Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4506-4513
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4506
Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report
Yong-Gang He, Zheng Wang, Jing Li, Wang Xi, Chong-Yu Zhao, Xiao-Bing Huang, Lu Zheng
Yong-Gang He, Zheng Wang, Jing Li, Wang Xi, Chong-Yu Zhao, Xiao-Bing Huang, Lu Zheng, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Co-first authors: Yong-Gang He and Zheng Wang.
Author contributions: He YG, Li J and Wang Z were responsible for writing the first draft; Xi W and Zhao CY participated in data acquisition and investigation. Supervision was performed by Huang XB and Zheng L. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. All the authors contributed to the study conception and design. He YG and Wang Z contributed equally to this work as co-first authors.
Supported by Chongqing Natural Science Foundation Project, No. CSTB2022NSCQ-MSX0172; and Incubation Project for Talented Young People, No. 2022YQB031.
Informed consent statement: The patient provided the written informed consent to participate in this study. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Zheng, Doctor, MD, PhD, Associate Specialist, Deputy Director, Doctor, Professor, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, No. 183 Xinqiao High Street, Shapingba District, Chongqing 400037, China. zhenglu@tmmu.edu.cn
Received: February 15, 2024
Revised: September 12, 2024
Accepted: September 20, 2024
Published online: November 15, 2024
Processing time: 252 Days and 19.6 Hours
Core Tip

Core Tip: Patient-derived tumor organoids have been demonstrated to improve the efficacy of conversion therapy by identifying individual-targeted effective drugs. Here we described a patient with hepatocellular carcinoma (HCC) who achieved pathologic complete response to conversion therapy guided by the patient-derived organoid (PDO) drug sensitivity testing. This typical case suggests that PDO-based drug sensitivity testing contributes to screening sensitive drugs for HCC patients to realize the personalized treatment and to improve the efficacy of conversion therapy, which may change the previous experiential therapy and serve as a novel treatment mode in liver cancer.